Also, in clinical practice, the risk of symptomatic ICHs after tPA treatment was found to be significantly higher in patients with more cerebral microbleeds present before administration of tPA (Tsivgoulis et al., 2016). The gene discussed is PLAT; the disease is cerebral microbleeds.